Analyst Group: Analyst Group's Comment on STENOCARE’s Q4-report Report 2024
STENOCARE A/S (STENOCARE or the “Company”) published on February 27th the Company’s Q4-report for 2024.
The following are some key points that we have chosen to highlight in connection with the report:
- Sales above guidance and our estimates
- Astrum oil is now available in three countries
- The result was affected by a special item – operational EBITDA better than our estimates
- Strengthened financial position through a rights issue after the end of Q4-24
To summarize, STENOCARE delivered a report where sales were above guidance and our estimate, as well as an operational EBITDA result, excluding special items, that was above our expectations. The medical cannabis market has proven challenging to penetrate, partly due to high competition and partly due to widespread skepticism toward cannabis among prescribing doctors. STENOCARE is therefore expected to place greater focus on educating doctors about the benefits of medical cannabis treatment, thereby driving growth, where we see the Astrum Oil as an important growth driver as it distinguishes STENOCARE from competitors as a first mover in the next generation of medical cannabis.
Read Analyst Group’s comment on the report here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on STENOCARE. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.